GLP-1 and Pregnancy

GLP-1 receptor agonists including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are contraindicated in pregnancy — animal studies show fetal harm at doses comparable to human exposures.

The recommended washout period before trying to conceive is at least 2 months for semaglutide and 1 month for liraglutide. GLP-1-driven weight loss actually improves fertility in women with obesity-related anovulation and PCOS.

Understanding the complete picture — when to stop, washout timing, what to do if pregnant while on medication, and breastfeeding guidance — is essential for women of reproductive age on GLP-1 therapy.

Medication Pregnancy Status Recommended Washout Breastfeeding

Animal studies with semaglutide, liraglutide, and tirzepatide have shown dose-dependent fetal harm — including embryo-fetal mortality, skeletal abnormalities, and impaired fetal growth — at exposures comparable to human therapeutic doses.

While human data are limited (pregnant women are excluded from clinical trials), the animal data are concerning enough for a clear contraindication. Additionally, GLP-1-induced caloric restriction and potential nutritional deficiencies could compromise fetal development.

There is an ongoing Novo Nordisk pregnancy registry (Motivate) collecting safety data from women who conceive on semaglutide, but results are not yet available. The 2-month washout recommendation for semaglutide is based on its long half-life (~1 week for the subcutaneous formulation) — approximately 5 half-lives are needed for near-complete drug elimination.

If you discover you are pregnant while on a GLP-1 medication, stop immediately and contact your prescribing physician and obstetrician. Do not attempt to .

An important and often overlooked benefit: GLP-1-mediated weight loss in obese women frequently improves fertility before any pregnancy attempt.

Obesity causes anovulation (absent ovulation) through multiple mechanisms — hyperinsulinemia driving excess androgen production, elevated leptin signaling disrupting hypothalamic-pituitary-ovarian axis function, and chronic inflammation impairing follicular development.

GLP-1 medications address all three: they reduce insulin levels, promote weight loss that normalizes leptin, and have direct anti-inflammatory effects. Women with PCOS (polycystic ovary syndrome) — the most common cause of anovulatory infertility — experience improved menstrual regularity and spontaneous ovulation with GLP-1-driven weight loss.

This means women on GLP-1 medications may become pregnant unexpectedly when previously they were anovulatory. Active and effective contraception is strongly recommended for all women of reproductive age on GLP-1 therapy who are not actively trying to conceive — and contraceptive effectiveness may be altered during early therapy if oral contraceptives are used alongside GLP-1 therapy (reduced GI absorption).

Long-acting reversible contraceptives (IUDs, implants) are not affected.

Semaglutide is not considered safe during pregnancy and is contraindicated by the FDA and all major prescribing guidelines. Animal studies demonstrated fetal harm including embryo-fetal mortality and skeletal malformations at doses comparable to human therapeutic exposures.

Human data are very limited since pregnant women are excluded from clinical trials — but the animal safety signals are sufficiently concerning for a clear contraindication. If you become pregnant while taking semaglutide (Ozempic or Wegovy), stop the medication immediately and notify your prescribing physician and OB/GYN.

Do not restart until after delivery and cessation of breastfeeding. There is an ongoing pregnancy exposure registry (Motivate) collecting safety data — ask your physician about enrollment if you have been inadvertently exposed during early pregnancy.

The recommended washout period for semaglutide before attempting conception is at least 2 months (approximately 8 weeks).

This recommendation is based on semaglutide's pharmacokinetics — it has an elimination half-life of approximately 1 week for the subcutaneous formulation, meaning complete elimination takes approximately 5–7 half-lives (5–7 weeks).

The 2-month recommendation provides a safety buffer beyond complete pharmacological elimination. Practical planning: if you are planning pregnancy, discuss timing with your prescribing physician at least 3 months in advance.

If you need ongoing treatment for T2D during the washout and pregnancy period, your physician may you to insulin, which has a well-established pregnancy safety profile. For obesity management during pregnancy, lifestyle intervention is the standard approach.

Resume GLP-1 therapy postpartum after completing breastfeeding, if appropriate.

Yes — GLP-1 medications can significantly improve fertility in women with obesity-related reproductive dysfunction, particularly those with PCOS (polycystic ovary syndrome) and anovulatory infertility.

The mechanism: GLP-1-driven weight loss of as little as 5–10% of body weight can restore regular menstrual cycles and spontaneous ovulation in women with obesity-related anovulation. Reductions in hyperinsulinemia and androgen excess with GLP-1 therapy directly improve the PCOS hormonal environment.

Multiple case series describe women who were previously struggling with infertility conceiving naturally after starting GLP-1 therapy and losing weight. This is both a therapeutic benefit and a clinical caution: women who believe they are infertile due to obesity or PCOS should use effective contraception on GLP-1 therapy unless actively trying to conceive — and should plan the appropriate 2-month washout period before conception attempts to ensure safe fetal development.

Clinical Evidence GLP-1 and Pregnancy protocols are supported by clinical research — Shotlee helps you track your own data against published benchmarks. Protocol Tracking Log each dose with exact timing and amount.

Consistent records help you and your provider optimize your protocol. Outcome Monitoring Track your key metrics before and during treatment. Objective data leads to better decisions than memory alone. Side Effect Log Record reactions immediately after each dose.

Pattern detection prevents minor issues from becoming serious problems. Progress Trends Shotlee charts your data over weeks and months — see long-term trends that individual data points can hide. Data-Driven Dosing Your logged data tells you what works.

Use Shotlee charts to make evidence-based adjustments to dose and timing.